The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...